Les récepteurs à Epidermal Growth Factor (REGF), une nouvelle cible thérapeutique

This publication has 9 references indexed in Scilit:

• EGFR and cancer prognosis
  Published by Elsevier ,2001
• The EGFR as a target for anticancer therapy—focus on cetuximab
  European Journal Of Cancer, 2001
• Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer
  Journal of Clinical Oncology, 2001
• The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy
  European Journal Of Cancer, 2001
• Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
  Journal of Clinical Oncology, 2000
• Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results
  Investigational New Drugs, 1999
• A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
  British Journal of Cancer, 1999
• Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
  JNCI Journal of the National Cancer Institute, 1998
• Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas
  Head & Neck, 1991